Rashmi Mehta
About
Rashmi Mehta is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Analytical Chemistry.
According to data from OpenAlex, Rashmi Mehta has authored 67 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Physiology, 40 papers in Pulmonary and Respiratory Medicine and 8 papers in Analytical Chemistry. Recurrent topics in Rashmi Mehta's work include Asthma and respiratory diseases (36 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers) and Inhalation and Respiratory Drug Delivery (26 papers). Rashmi Mehta is often cited by papers focused on Asthma and respiratory diseases (36 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers) and Inhalation and Respiratory Drug Delivery (26 papers). Rashmi Mehta collaborates with scholars based in United States, United Kingdom and Canada. Rashmi Mehta's co-authors include Alison Church, Glenn Crater, Sally Kilbride, Chris Kalberg, James F. Donohue, M. Reza Maleki-Yazdi, Andrew Preece, Jean Brooks, Dennis Kelleher and Maggie Tabberer and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and CHEST Journal.
In The Last Decade
Rashmi Mehta
64 papers receiving 1.1k citations
Peers
Rashmi Mehta
G P Ventresca Italy
Johan Rosenborg Sweden
Ann Allen United Kingdom
Jens Markus Borghardt Germany
Thomas D. Bell United States
Ruediger Nave Japan
Leigh M. Vaughan United States
Denis O’Donnell Canada
Robert L. Kunka United States
Helmut H. Albrecht United States
Citations per year, relative to Rashmi Mehta Rashmi Mehta (= 1×)
peers
G P Ventresca
Countries citing papers authored by Rashmi Mehta
Since
Specialization
Citations
This map shows the geographic impact of Rashmi Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rashmi Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rashmi Mehta more than expected).
Fields of papers citing papers by Rashmi Mehta
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rashmi Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rashmi Mehta. The network helps show where Rashmi Mehta may publish in the future.
Co-authorship network of co-authors of Rashmi Mehta
This figure shows the co-authorship network connecting the top 25 collaborators of Rashmi Mehta. A scholar is included among the top collaborators of Rashmi Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rashmi Mehta. Rashmi Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gupta, R. K., et al.. (2025). Revisiting the Synergistic In Vitro Antimicrobial and Antibiofilm Potential of Chlorhexidine Gluconate and Cetrimide in Combination as an Antiseptic and Disinfectant Agent. Microbiology Research. 16(1). 16–16.
2.
Mehta, Rashmi, Konstantinos Angelis, Lesley Kahl, et al.. (2023). Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. 89(7). 2190–2200.
3.
Carreño, F., et al.. (2023). Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for Linerixibat. Clinical Pharmacology & Therapeutics. 115(2). 288–298.
4.
Mehta, Rashmi, Joseph Piscitelli, Adrian J. Wolstenholme, et al.. (2020). The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet. SHILAP Revista de lepidopterología.
5.
Moore, Alison, et al.. (2017). Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30(3). 164–172.
6.
Mehta, Rashmi, et al.. (2016). Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 29(4). 386–392.
7.
Hu, Chaoying, Jingying Jia, Kelly Dong, et al.. (2015). Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial. PLoS ONE. 10(3). e0121264–e0121264.
8.
Kelleher, Dennis, Lee Tombs, Andrew Preece, Noushin Brealey, & Rashmi Mehta. (2014). A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 29(1). 49–57.
9.
Celli, Bartolomé R., Glenn Crater, Sally Kilbride, et al.. (2014). Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD. CHEST Journal. 145(5). 981–991.
10.
Church, Alison, et al.. (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulmonary Medicine. 14(1). 2–2.
11.
Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2014). Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study. Clinical Therapeutics. 36(7). 1016–1027.e2.
12.
Daley‐Yates, Peter T., et al.. (2013). Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol Delivered as a Combination Dry Powder from a Capsule-Based Inhaler and a Multidose Inhaler in Asthma and COPD Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(4). 279–289.
13.
Donohue, James F., Antonio Anzueto, Jean Brooks, et al.. (2012). A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respiratory Medicine. 106(7). 970–979.
14.
Decramer, Marc, François Maltais, Gregory Feldman, et al.. (2012). Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respiratory Physiology & Neurobiology. 185(2). 393–399.
15.
Bateman, Eric, Gregory Feldman, Sally Kilbride, et al.. (2012). Efficacy and safety of the long‐acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. The Clinical Respiratory Journal. 6(4). 248–257.
16.
Blake, Kathryn, Rashmi Mehta, Terry Spencer, Robert L. Kunka, & Leslie Hendeles. (2011). Bioavailability of inhaled fluticasone propionateviachambers/masks in young children. European Respiratory Journal. 39(1). 97–103.
17.
Kelleher, Dennis, Andrew Preece, Rashmi Mehta, et al.. (2011). Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD). European Respiratory Journal. 38(Suppl 55). p834–p834.
18.
Mehta, Rashmi, Amy Newlands, Dennis Kelleher, et al.. (2011). Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD. European Respiratory Journal. 38(Suppl 55). p822–p822.
19.
Mehta, Rashmi & Diane K. Hartle. (1994). Effects of total fasting or chronic food restriction on plasma endothelin levels in rats. Physiology & Behavior. 56(2). 407–410.
20.
Mehta, Rashmi, et al.. (1993). SHORT COMMUNICATION: The effects of patterned calorie-restricted diets on mammary tumor incidence and plasma endothelin levels in DMBA-treated rats. Carcinogenesis. 14(8). 1693–1696.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by G P Ventresca Breakdown of academic impact, for papers by Johan Rosenborg Breakdown of academic impact, for papers by Ann Allen Breakdown of academic impact, for papers by Jens Markus Borghardt Breakdown of academic impact, for papers by Thomas D. Bell Breakdown of academic impact, for papers by Ruediger Nave Breakdown of academic impact, for papers by Leigh M. Vaughan Breakdown of academic impact, for papers by Denis O’Donnell Breakdown of academic impact, for papers by Robert L. Kunka Breakdown of academic impact, for papers by Helmut H. Albrecht